RedHill Biopharma Ltd. (RDHL)
After hours:
| Previous Close | 7.95 |
| Open | 8.08 |
| Bid | 5.82 x 200 |
| Ask | 10.17 x 200 |
| Day's Range | 7.90 - 8.42 |
| 52 Week Range | 6.80 - 82.00 |
| Volume | |
| Avg. Volume | 78,080 |
| Market Cap | 10.782M |
| Beta (5Y Monthly) | 3.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -302.63 |
| Earnings Date | Aug 29, 2024 - Sep 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19,000.00 |
PR NewswireRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been selected to further elaborate on opaganib's[1] potential in a presentation to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day". The meeting is scheduled to take place October 29-30, 2024, at the United States Paten
TipRanksRedHill Biopharma and Duke Collaborate on Opaganib Development
RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has announced a collaboration with Duke University School of Medicine to test the drug opaganib as a treatment for phosgene inhalation injury, a potential public safety threat. The partnership aims to advance opaganib development under FDA guidelines, addressing the lack of approved antidotes for this toxic industrial chemical. Opaganib’s broad potential applications and its ongoing evaluation by U.S. government programs highligh
- PR Newswire
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a collaborative research agreement with Duke University School of Medicine outlining plans for multiple in vivo studies. The program is designed to test opaganib[2] as a potential medical countermeasure to treat phosgene inhalation injury, aimed at providing results sufficient to advance opaganib into further definitive U.S. government-sponsored development un
